Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

ear:

- YM USA was cleared by the US FDA to expand its second-line clinical

trial in children with inoperable, recurrent, treatment-resistant

brain cancer into the US

- Oncoscience AG reported completion of patient enrolment in the

Phase III, first-line, pediatric brain cancer trial.

- Oncoscience AG reported initiation of late-stage trials in adult

glioma and pancreatic cancer.

- YM reported positive preliminary results of a Phase I/II trial of

nimotuzumab in combination with radiation for the treatment of

non-small-cell lung cancer (NSCLC).

- The first 20 patients were recruited into the Phase II colorectal

trial by the date of this release.

AeroLEF(TM):

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF(TM) permits patients to identify and select the appropriate dose in real-time for each pain episode to achieve both rapid onset and extended duration of analgesia.

During Fiscal 2007:

- YM announced that AeroLEF(TM) had met the primary endpoint in its

first randomized, placebo-controlled Phase IIb trial enrolling opioid-

naive patients with post-operative pain following orthopedic surgery.

A statistically significant difference in pain relief and pain

intensity to placebo (p=0.0194) was reported.

- YM received clearance from the FDA to initiate a Phase II trial in the

US in opioid tolerant or opioid-naive patients. A successful trial

would further extend the utility and medical breadth of the product if

and when approved. Enrollment in its 50-patient trial is expected to

start in calendar Q4, 2007.

- A request to the FDA for an End-of-Phase II meeting prior to calendar

year-end 2007 to discuss Phase III trial desi
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 Rust removal is ... and non-metal home items could be damaged. To help rust ... use of its no-scrubbing rust remover it called ... able available with 10% discount. , My Cleaning Products explained ... corroding them or by staining them. The first one, ...
(Date:5/16/2013)... 16, 2013 ISPE ... Myers, CAE, to the newly created position of ... role, Myers will be responsible for stimulating ISPE’s ... strategies, advancing the Society’s Member-led and staff-driven business ... to refine organizational, membership and product marketing. , ...
(Date:5/16/2013)... May 16, 2013 Cambridge Healthtech Institute ... August 19-23, 2013 at the Renaissance Waterfront Hotel in ... provide a close-up look at the current strategies and ... bottom-line quality. Leaders in the field will reveal ... produce biopharmaceuticals with greater specificity and efficiency. , “In ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Excellence and Patient Ease-of-Use, BROOKFIELD, Wis., April ... won the 2008 Medical Design Excellence Awards (MDEA) ... Genesis DM won in the,rehabilitation and assistive-technology products ... monitoring device is,ideal for both the patient and ...
... Replikins Ltd. has found that the,Replikin Count(TM) of the ... (plus/minus 1.4), its highest level since the 1918 H1N1,pandemic ... of a particular,influenza strain, indicating rapid replication of the ... by an outbreak of the specific,strain. The current increase ...
... 2008 A,cross-disciplinary research team at the University of ... drug research platform can,produce the chemical reactions needed to ... on a tiny "biochip" created to mimic,the environment within ... This means that the researchers can proceed to the ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 3U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 4
(Date:5/17/2013)... of all ages will celebrate the science and ... our daily lives during the inaugural Atlanta Science ... educators from local museums, corporations, K-12 schools and ... different events for children and adults at venues ... . , The annual Atlanta Science Festival ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
(Date:5/16/2013)... to a fast food restaurant had a higher body ... from fast food, according to researchers at The University ... was particularly strong among those with a lower income. ... American Journal of Public Health indicates higher ... restaurant, and among lower-income African-Americans, the density, or number, ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... famed starship Enterprise would deploy a deflector shield to evade ... molecular force field of their own to fend off treatments ... found a chink in their armor. , The cells churn ... protective barrier that deflects damage from radiation or chemotherapy and ...
... study of more than 68,000 infants published in this ... Rotateq demonstrated that it can safely prevent 98 percent ... account for 2 million hospital visits and 500,000 pediatric ... largest pre-licensure vaccine clinical trials ever conducted worldwide, research ...
... the University of Pennsylvania, demonstrate that biodegradable nano-particles ... killing human breast tumors. The unique properties ... allow them to deliver two distinct drugs, paclitaxel, ... such as Taxol, and doxorubicin directly to tumors ...
Cached Biology News:Molecular force field helps cancer cells defend against attack 2Molecular force field helps cancer cells defend against attack 3New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3Nano-particles effective in killing cancer with one-two punch of chemotherapeutics 2
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
...
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
Biology Products: